Literature DB >> 16871278

Screening of JAK2 V617F mutation in multiple myeloma.

A Fiorini, G Farina, G Reddiconto, M Palladino, E Rossi, T Za, L Laurenti, S Giammarco, P Chiusolo, G Leone, S Sica.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16871278     DOI： 10.1038/sj.leu.2404332

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  6 in total

1.  High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation.

Authors:  T Nishihori; Y Hassoun; L Zhang; K Shain; M Alsina; M A Kharfan-Dabaja
Journal:  Bone Marrow Transplant       Date:  2013-08-12       Impact factor: 5.483

2.  Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity.

Authors:  Seiichi Odate; Veronica Veschi; Shuang Yan; Norris Lam; Richard Woessner; Carol J Thiele
Journal:  Clin Cancer Res       Date:  2016-10-19       Impact factor: 12.531

Review 3.  Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

Authors:  Faiz Anwer; Kevin Mathew Gee; Ahmad Iftikhar; Mirza Baig; Atlantis Dawn Russ; Sabina Saeed; Muhammad Abu Zar; Faryal Razzaq; Jennifer Carew; Steffan Nawrocki; Hussam Al-Kateb; Nadia Nunes Cavalcante Parr; Ali McBride; Jason Valent; Christy Samaras
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-03-25

4.  Pathogenic signaling in multiple myeloma.

Authors:  Arnold Bolomsky; Ryan M Young
Journal:  Semin Oncol       Date:  2022-01-20       Impact factor: 5.385

5.  The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Authors:  Barry Paul; Yue Zhao; Gavin Loitsch; Daniel Feinberg; Parker Mathews; Ian Barak; Megan Dupuis; Zhiguo Li; Lindsay Rein; Endi Wang; Yubin Kang
Journal:  Cancer Med       Date:  2020-07-06       Impact factor: 4.452

6.  Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.

Authors:  Shuang Yan; Zhijie Li; Carol J Thiele
Journal:  Oncotarget       Date:  2013-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.